Recent ELEV News
- Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors • PR Newswire (US) • 12/12/2024 12:30:00 PM
- Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 • PR Newswire (US) • 12/05/2024 12:30:00 PM
- Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference • PR Newswire (US) • 11/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2024 09:15:11 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/15/2024 12:05:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 12:45:20 PM
- Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements • PR Newswire (US) • 11/06/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 12:00:40 PM
- Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 • PR Newswire (US) • 09/23/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:15:12 PM
- Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:15:08 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:45:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:30:28 AM
- Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements • PR Newswire (US) • 08/06/2024 11:10:00 AM
- Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 • PR Newswire (US) • 08/06/2024 11:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/15/2024 05:17:58 PM
- Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer • PR Newswire (US) • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:30:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:28:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:10:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/10/2024 04:15:22 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/09/2024 08:39:05 PM
- Elevation Oncology to Present at the Citizens JMP Life Sciences Conference • PR Newswire (US) • 05/07/2024 11:30:00 AM
FEATURED Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM
UAV Corp's (UMAV), Skyborne Technology to Build "SKY" Hangar at Its Costin Airport Scheduled for Groundbreaking Ceremony Winter 2025 • UMAV • Dec 20, 2024 8:30 AM
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM